NDC 13811-715 – Venlafaxine Hydrochloride
Venlafaxine Hydrochloride 225 mg/1 · Tablet, Extended Release · Oral
Product NDC13811-715
Product details
- Brand name
- Venlafaxine Hydrochloride
- Generic name
- Venlafaxine hydrochloride
- Labeler
- Trigen Laboratories, LLC
- Dosage form
- Tablet, Extended Release
- Route
- Oral
- Marketing category
- NDA AUTHORIZED GENERIC · NDA022104
- Marketed since
- April 29, 2010
- Marketing end
- September 30, 2026
- Pharmacologic class
- Serotonin and Norepinephrine Reuptake Inhibitor
Active ingredients
- Venlafaxine Hydrochloride 225 mg/1
Uses, dosage, side effects and warnings for Venlafaxine Hydrochloride →
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 13811-715-30 | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (13811-715-30) | Apr 29, 2010 |
Other Venlafaxine Hydrochloride products
- 80425-0477 Venlafaxine Hydrochloride 37.5 mg/1 · Tablet, Extended Release · Advanced Rx of Tennessee, LLC
- 68001-496 Venlafaxine Hydrochloride 37.5 mg/1 · Tablet, Extended Release · BluePoint Laboratories
- 68001-499 Venlafaxine Hydrochloride 225 mg/1 · Tablet, Extended Release · BluePoint Laboratories
- 68001-498 Venlafaxine Hydrochloride 150 mg/1 · Tablet, Extended Release · BluePoint Laboratories
- 68001-497 Venlafaxine Hydrochloride 75 mg/1 · Tablet, Extended Release · BluePoint Laboratories
- 31722-126 Venlafaxine Hydrochloride 225 mg/1 · Tablet, Extended Release · Camber Pharmaceuticals, Inc.
- 31722-123 Venlafaxine Hydrochloride 37.5 mg/1 · Tablet, Extended Release · Camber Pharmaceuticals, Inc.
- 31722-124 Venlafaxine Hydrochloride 75 mg/1 · Tablet, Extended Release · Camber Pharmaceuticals, Inc.
- 31722-125 Venlafaxine Hydrochloride 150 mg/1 · Tablet, Extended Release · Camber Pharmaceuticals, Inc.
- 75834-217 Venlafaxine Hydrochloride 75 mg/1 · Tablet, Extended Release · Nivagen Pharmaceuticals, Inc.
- 75834-218 Venlafaxine Hydrochloride 150 mg/1 · Tablet, Extended Release · Nivagen Pharmaceuticals, Inc.
- 75834-219 Venlafaxine Hydrochloride 225 mg/1 · Tablet, Extended Release · Nivagen Pharmaceuticals, Inc.